On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation. The patent world is watching, particularly those who focus on emerging technologies. On March 14, 2013, the NanoBusiness Commercialization Association filed a brief in support of Myriad Genetics (brief prepared by Foley & Lardner, LLP). In addition to arguing that the patent claims should be patent eligible, which is the essence of the case, the brief also argues that patents do not preempt others from experimenting on, improving upon, or designing around a patented invention. With today being the first day of the new first-to-file regime, patent lawyers of all stripes are busy these days keeping up with dramatic changes to the patent system. The Supreme Court could use the Myriad case to establish a new paradigm for patent eligibility. Stay tuned.
Related Insights
July 11, 2025
Foley Viewpoints
Department of Justice Launches Program to Reward Antitrust Whistleblowers with Shares of Criminal Fines
On July 8, 2025, the U.S. Department of Justice, Antitrust Division (“Antitrust Division”) announced a new “Whistleblower Rewards…
July 23, 2025
Events
Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact
Foley partner Monica Chmielewski, vice chair of the firm’s Health Care Practice Group, is speaking in Strafford’s upcoming webinar titled “Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact” on July 23.
September 30, 2025
Events
FDA Regulation of AI-Enabled Medical Devices
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking at the American Bar Association Health Law Section’s Healthcare Delivery & Innovation Conference on September 30.